CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Estradiol +1 moredrug
Likely dose
Estradiol 100μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02255175
NCT02255175Phase 4Completed
CompareCT.gov

Effects of Estradiol on Neural Reward System and Depression in the Perimenopause

University of North Carolina, Chapel Hill·interventional·Posted Oct 2, 2014·Updated Nov 12, 2019

In Brief

A Phase 4 clinical trial evaluating Estradiol and Progesterone for Perimenopausal Depression. Completed, enrolled 64 participants across 1 site.

Detailed Summary

Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerimenopausal Depression
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2, 2014
Enrollment StartOct 1, 2015
Primary CompletionOct 17, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.8 years ago

Interventions

Estradioldrug

Participants will receive transdermal estradiol (100μg/day) for 3 weeks

Progesteronedrug

Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.